Epilepsy beginning in young dogs requires careful welfare management balancing seizure control against drug side effects. Evidence-based anticonvulsant therapy significantly improves quality of life.
Epileptic seizures cause significant acute welfare harm. During a seizure, dogs lose consciousness, experience uncontrolled muscle activity, salivate, urinate, and defecate. The post-ictal phase — lasting minutes to hours — involves confusion, blindness, hunger, and weakness. The acute seizure experience and its aftermath are welfare-relevant negative events regardless of the dog's subsequent recovery.
Cluster seizures (multiple seizures within 24 hours) and status epilepticus (seizures lasting more than 5 minutes) are welfare emergencies with life-threatening potential. Emergency diazepam or midazolam administration at home, provided by trained owners, can abort cluster seizures and prevent escalation to status epilepticus. All epileptic dog owners should be trained in and equipped with emergency seizure medication.
The goal of anticonvulsant therapy is minimizing seizure frequency and severity while minimizing drug side effects — both sides of the equation are welfare-relevant. Phenobarbitone is highly effective but requires liver monitoring; KBr provides additive control; newer drugs like levetiracetam offer good efficacy with different side effect profiles. Combination therapy achieves seizure control in many refractory cases. Regular quality of life assessment guides treatment adjustment.